{"name":"ASC Therapeutics","slug":"asc-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ASC618","genericName":"ASC618","slug":"asc618","indication":"Other","status":"phase_1"},{"name":"ASC930","genericName":"ASC930","slug":"asc930","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ASC618","genericName":"ASC618","slug":"asc618","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ASC930","genericName":"ASC930","slug":"asc930","phase":"phase_2","mechanism":"ASC930 is a small molecule that targets the [insert target here, if known].","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPTUhWSkY2Y0c5MlJZMmFXYUI2VXA5UjhrZ29mMXMzR3dmSGhqY1FzSGRmcGU0THNhR1dTaWI3eFFDNnplTEFwdlRoQ3huS3VYMm52VkI0anhXTGg4dmdKRHFxX0FEc2FCdjc0SzNhbEllbllNZkE0eVJOeFp6a1N5WC1pRU9sWnFRVTZZVXBwcWVOWloxOGowV0VSRDFVa1R2NGtfdGt0eTRGeVBzRzJRaWFJR2FsRXNLWnh0T2dxeXV4YUZkMklfOG1ZbEFFeVd1Q2drZzN3RTFQQQ?oc=5","date":"2026-03-19","type":"pipeline","source":"Barchart.com","summary":"Hemophilia Clinical Development Landscape Strengthens as 80+ Companies Drive Innovation | DelveInsight - Barchart.com","headline":"Hemophilia Clinical Development Landscape Strengthens as 80+ Companies Drive Innovation | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOcmV3RXdxbDFMZFE1UlIxbjdDNEZiYVBSWXpRZXZMY3I4bGdQdk9DRm93YnRnQWw3aUpIb1pmUER1Z1FmR3VHNmtNUFVmQ001cVctSV9PZDgyaVZNQkYyQldKR25jUElPY3hucFU3alZiUWxjQ203Y3J5QTI3elpCb19RUmRuNkdiYmhmV2dSNENCVDBLUHhhM2V6WERJSFJUQVFjUHd0TTZFdllpb25aUWNrYjVDWXJrR0I2MlAySjdpelVKLWlpZmtDcGpfS05OaGxuTGhuQQ?oc=5","date":"2025-12-15","type":"pipeline","source":"European Pharmaceutical Review","summary":"AI-discovered IL-17 inhibitor from Ascletis Pharma shows best-in-class potential - European Pharmaceutical Review","headline":"AI-discovered IL-17 inhibitor from Ascletis Pharma shows best-in-class potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQS1VHdUdiMXFwWk5PU1NJc2k3dE9JeU84MmtYMlpONE9udUhzTEZLQ29iS2pEcm5Nbkw4bkhnclFhUXdrWFJ5ZURCX3FOdUg3dWxYNFBiRTg1eUxoUFhHTF9xVTEzYnJkV2VFY3pEM25XdlBEQlhteEc2MEhuanlEQll4WV90Z1o0a3ZJYU5XMmRZWXRlMFN5enRDekxwaVpmNUFDTXo2am0?oc=5","date":"2025-12-08","type":"pipeline","source":"BioWorld News","summary":"Wave Life, Structure and Ascletis post wins in obesity management - BioWorld News","headline":"Wave Life, Structure and Ascletis post wins in obesity management","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-03","type":"pipeline","source":"PR Newswire","summary":"Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Th","headline":"Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOT0otTnQ1QW92dXB2UW1fdDNmQmNVUGlIWWVKZFBxbFZqNXNTSjAyNExEUUpLREZfZHJwaFk2NlVaaThNZGZlYjcwSWFLblZHcUV4bVNFS0d2bXVnaDZ0QVJlVklDcXFWV05GNUx3MHo1V1BCTnB6UmxxWTF2dG9BdTVwclVRTWwwNnpmV2VmQXhZOHMtN0E?oc=5","date":"2025-11-26","type":"pipeline","source":"Medical Marketing and Media","summary":"Rx Rundown: Novo Nordisk, Mayne Pharma, Quarry Thera and more - Medical Marketing and Media","headline":"Rx Rundown: Novo Nordisk, Mayne Pharma, Quarry Thera and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPRUZaUFdZcTJzVGtkQ01VcGxFLWg0UGlQTkJ0UEl0MjJ3QjU4UkRqWjBlQjYxUjVNMlQ4SVRwQVV5SW84Z0xKdXpjQk1kVE9RaTVrZFNoUFY3alpJZHpqbmQxcEduUWdLQmdOd1lROEhNYzBwM0xQWFVOYnhVandhYjhrOWFHZUZDTllTdmp1NHE1OHJIYVRuQ0k0SnItbWZkM3RCTl9qbXRNb0s5Mmc?oc=5","date":"2025-11-17","type":"pipeline","source":"Dermatology Times","summary":"Beyond Antibiotics: How Oral Denifanstat Could Reshape the Acne Pipeline - Dermatology Times","headline":"Beyond Antibiotics: How Oral Denifanstat Could Reshape the Acne Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOZlBGRXdkNVlaMXd1TmdONFBqaG5HT2c3NHVBX0hyZkJtMkFWSlZfbXNmYzZTWlQ3Z1VEQy1wUi0xUWw0aGdBQ3Rjel9ic0JCWUNMS3Zua0drVWRmc3FlRTdkbTg1R2M3cG1xTkhWU3FRUGRzdTdKNjV0YklTR0YzVkJzamdJbllxRXQxWjBQV3FoRExmWVlJdHNGV25zaEFZYUlNWkZVdkU4WXRnVFc1akRHOXdHanhmRmszNGFHekRlTDd5VzM0NG9mbU1tNW5NNDNkVEZLa0ZmOFNkV09sMkRwcEg4ZUlmc2VIMWlNWQ?oc=5","date":"2025-06-12","type":"pipeline","source":"PR Newswire","summary":"4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight - PR Newswire","headline":"4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE95d2dFeTBGYjJvY052ZzRTLXE2VnQ0WlFpMVhmTl96aUw2WE1pYU92UTRjLWo3X21QQk0wXzFxVVRiN0xqTGlxMkNFU1hkSzhKNW1B?oc=5","date":"2025-02-19","type":"trial","source":"FirstWord Pharma","summary":"Ascletis shows Chinese innovation is still hot with early oral GLP-1 data - FirstWord Pharma","headline":"Ascletis shows Chinese innovation is still hot with early oral GLP-1 data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQVUFVZ2NEblJPTk5qeC1RM2lvV3Nub1dMdFlMTHV6NzdwQkN2aTFVcjhNNklrWGNIbmYyS0wyNmhGSGJmZXhwSUY3bHI4VnFkb2FVd0lKblpUYU5WV1RXNG5TM0h3bzdpTTJKQ3pmYUlKYXFUNkJzTWt1ejVreHlWVUNTajhsR18yZWs0M1BBRQ?oc=5","date":"2024-08-02","type":"trial","source":"Clinical Trials Arena","summary":"Pfizer’s haemophilia A gene therapy shows promise, but tough rivals ahead - Clinical Trials Arena","headline":"Pfizer’s haemophilia A gene therapy shows promise, but tough rivals ahead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQbmZzMnoza2d2WlRtVExvYmxQM0k2UGEzLTlnZ2FfNEl5cHNtZUpLWTVoS09IalZHSUtjOUNxUWIzUTVjdExhZnp4eTN4UnVfTmxibDdDS0lkdE92ZmpuQ2prY3UyM1kxOTZwSmNTN0R4ckwyYUl3TWpMeUdYS1JUeVBwSHlVUktmVFlWRkNTTnEwUFA0MmNfMWZoT25IQ0tjaVJOdHMtNnhRWEREWjRQVzBlZndHLUl0eTlpTHZvMS04RDg4N0I2WWx5M1REalRMa0tGb0doaEExcWJJZ2pJRTBZcEtrOTZH?oc=5","date":"2023-11-29","type":"pipeline","source":"Business Wire","summary":"ASC Therapeutics Doses First Patient with ASC618 Second-Generation Gene Therapy for Hemophilia A - Business Wire","headline":"ASC Therapeutics Doses First Patient with ASC618 Second-Generation Gene Therapy for Hemophilia A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPeDd1aFB3TjlaTUMxZnB5Y2t4Z3J0Z3B6VjdodUtBdzdmVldBZ0MzTzFmWld2VHZEa3dRLVV3SXZnRENTWk52VnNfN0FBMkVlVVFZZTVHSnh0eFRUR01EZE1pbThXMURGb2ZuZGNCVmY1Ykk3b19IUHh4bDlZa3N2LXVPLVVsV0U?oc=5","date":"2023-10-18","type":"pipeline","source":"clinicalleader.com","summary":"DCTs Can Work, But Expect More Time & Costs - clinicalleader.com","headline":"DCTs Can Work, But Expect More Time & Costs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZHBVeW1iWm5WUzJGUEdJRS1FQ1g2Rm90ZThNbm10QUZHcVIxalZxalFrR2FwNHRlRTJOOUR2SThnQ3BfNzFIWW10WEhyMkkzQnk1enAxNmlGbVFBdDVZeFo0LTJWdXo4NkFhMzc2MFhXbVJLRmZyUEJJTkxhOWhPZVJsekZBSVZ0TnZkbmRuZ3hERm5OdW9CWkxKUi1WUFBLZldOR1FXUThXUHRaVjhaajRoM2Q4SnNIeEVJLTgtblJ0Zw?oc=5","date":"2023-10-09","type":"deal","source":"Fierce Biotech","summary":"QHP buys Applied StemCell, adding cell and gene therapy specialist to pharma service portfolio - Fierce Biotech","headline":"QHP buys Applied StemCell, adding cell and gene therapy specialist to pharma service portfolio","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}